[HTML][HTML] Can VEGF reverse diabetic neuropathy in human subjects?
A Veves, GL King - The Journal of clinical investigation, 2001 - Am Soc Clin Investig
A Veves, GL King
The Journal of clinical investigation, 2001•Am Soc Clin InvestigSee related article, pages 1083–1092. reductase inhibitors, γ-linolenic acid, antioxidants
such as α lipoic acid, and nerve growth factors (7). Despite initial encouraging reports with
most of these agents, the results of large perspective controlled clinical trials have invariably
been negative, and none of the tested medications have been approved for use in this
country. Therefore, an urgent need exists to develop new therapeutic approaches that will
improve nerve function in diabetic patients.
such as α lipoic acid, and nerve growth factors (7). Despite initial encouraging reports with
most of these agents, the results of large perspective controlled clinical trials have invariably
been negative, and none of the tested medications have been approved for use in this
country. Therefore, an urgent need exists to develop new therapeutic approaches that will
improve nerve function in diabetic patients.
See related article, pages 1083–1092. reductase inhibitors, γ-linolenic acid, antioxidants such as α lipoic acid, and nerve growth factors (7). Despite initial encouraging reports with most of these agents, the results of large perspective controlled clinical trials have invariably been negative, and none of the tested medications have been approved for use in this country. Therefore, an urgent need exists to develop new therapeutic approaches that will improve nerve function in diabetic patients.
The Journal of Clinical Investigation